Related Experiment Video

Updated: Jul 13, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

The vasodilatory beta-blockers

Michala E Pedersen1, John R Cockcroft

  • 1Department of Cardiology, Wales Heart Research Institute, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.

Current Hypertension Reports
|August 10, 2007
PubMed

Insights

Newer vasodilating beta-blockers may improve cardiovascular outcomes by reducing central aortic pressure more effectively than traditional beta-blockers like atenolol. These drugs offer hemodynamic benefits, potentially leading to better stroke and mortality reduction.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-blockers are established treatments for hypertension and cardiovascular disease.
  • Clinical data suggest some beta-blockers (e.g., atenolol) may be less effective in reducing stroke and cardiovascular mortality compared to other antihypertensive classes, despite similar blood pressure reduction.

Purpose of the Study:

  • To explore the potential benefits of newer vasodilating beta-blockers in cardiovascular disease management.
  • To investigate the hemodynamic differences between vasodilating and nonvasodilating beta-blockers.

Main Methods:

  • Review of clinical trial data and hemodynamic profiles of various beta-blockers.
  • Comparison of effects on central aortic pressure, peripheral vascular resistance, cardiac output, and left ventricular function.
  • Analysis of vasodilating mechanisms (alpha(1)-receptor blockade, nitric oxide bioactivity).

Main Results:

  • Nonvasodilating beta-blockers (e.g., atenolol) may be less effective in reducing central aortic pressure, stroke, and cardiovascular mortality.
  • Vasodilating beta-blockers (carvedilol, labetalol, nebivolol) promote vasodilation and have favorable hemodynamic profiles.
  • These agents reduce peripheral vascular resistance while maintaining or improving cardiac output and left ventricular function, decreasing central aortic blood pressure.

Conclusions:

  • Vasodilating beta-blockers demonstrate beneficial hemodynamic effects, including reduced central aortic pressure, compared to conventional beta-blockers.
  • Further large-scale trials are necessary to confirm if these hemodynamic improvements translate to superior cardiovascular outcomes.

More Related Videos

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research08:42

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

Related Concept Videos

Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...